Drug Profile
Filgrastim biosimilar - Tanvex Biopharma
Alternative Names: Nypozi; TX-01Latest Information Update: 02 Jun 2023
Price :
$50
*
At a glance
- Originator Tanvex BioPharma
- Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants; Recombinant proteins
- Mechanism of Action Granulocyte colony stimulating factor receptor agonists; Granulocyte colony-stimulating factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Neutropenia
Most Recent Events
- 16 May 2023 Tanvex BioPharma enters into exclusive marketing agreement for filgrastim in Canada
- 16 May 2023 Tanvex Biopharma intends to launch filgrastim for Neutropenia in Canada in 2023
- 17 Mar 2021 Filgrastim biosimilar is still under regulatory review for Neutropenia in USA and Canada (Tanvex Biopharma pipeline, March 2021)